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To facilitate rapid, unbiased, differential diagnosis of
infectious diseases, we designed GreeneChipPm, a panmi-
crobial microarray comprising 29,455 sixty-mer oligonu-
cleotide probes for vertebrate viruses, bacteria, fungi, and
parasites. Methods for nucleic acid preparation, random
primed PCR amplification, and labeling were optimized to
allow the sensitivity required for application with nucleic
acid extracted from clinical materials and cultured isolates.
Analysis of nasopharyngeal aspirates, blood, urine, and tis-
sue from persons with various infectious diseases con-
firmed the presence of viruses and bacteria identified by
other methods, and implicated Plasmodium falciparum in
an unexplained fatal case of hemorrhagic feverlike disease
during the Marburg hemorrhagic fever outbreak in Angola
in 2004–2005.
R
apid differential diagnosis of infectious diseases is
increasingly important as novel pathogens emerge in
new contexts and treatment strategies are beginning to be
tailored to specific infectious agents. Because clinical syn-
dromes are rarely specific for single pathogens, unbiased
multiplex assays are essential. Methods for direct molecu-
lar detection of microbial pathogens in clinical specimens
are rapid, sensitive, and may succeed when fastidious
requirements for agent replication or the need for high-
level biocontainment confound cultivation. 
We have adopted a staged strategy for molecular
pathogen surveillance and discovery. In the first stage we
use MassTag PCR, a PCR platform wherein discrete mass
tags rather than fluorescent dyes serve as reporters. This
method, which allows simultaneous detection of >20 dif-
ferent pathogens with high sensitivity, has proven useful
for differential diagnoses of respiratory disease and viral
hemorrhagic fevers (1–3). However, it is not sufficient
when larger numbers of known pathogens must be consid-
ered, when new but related pathogens are anticipated, or
when sequence divergence might impair binding of PCR
primers. Thus, to address the challenge of more highly
multiplexed differential diagnosis, we established an
oligonucleotide microarray platform.
Microarrays have potential to provide a platform for
highly multiplexed differential diagnosis of infectious dis-
eases (4,5). The number of potential features per microar-
ray far exceeds those of any other known technology;
hundreds of thousands of features can be printed on 70-mm
× 20-mm slides. Furthermore, sequence probes of >70 nt
are not uncommon. Thus, microbes can be detected when
melting temperatures are high enough to allow hybridiza-
tion, despite a lack of precise complementarity between
probe and target. Lastly, microbial and host gene targets can
be incorporated, which provides an opportunity to detect
microbes and assess host responses for signatures consis-
tent with various classes of infectious agents. Despite these
advantages, microbial arrays have not been widely used
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1These authors contributed equally to this study.with clinical materials because of limited sensitivity. The
primary service of microbial arrays has been characteriza-
tion of agents propagated to high titer in vitro (6). 
We report establishment of a microarray platform for
pathogen surveillance and discovery, the GreeneChip sys-
tem. Its key features include a comprehensive microbial
sequence database for probe design and protocols for sam-
ple preparation, amplification, labeling, hybridization, and
analysis. The system has been optimized with cultured
viral isolates; tested with blood, respiratory, urine, and tis-
sue samples containing bacterial and viral pathogens; and
applied in an outbreak investigation when other methods




A vertebrate viral sequence database (GreeneVrdB)
was established by integrating the database of the
International Committee on Taxonomy of Viruses
(ICTVdB, http://phene.cpmc.columbia.edu), a database
that describes viruses at the levels of order, family, genus,
and species, and the sequence database of the National
Center for Biotechnology Information (NCBI, www.
ncbi.nih.gov). Functionally related sequences were clus-
tered by using the protein families (Pfam,
http://pfam.janelia.org) database of alignments (7). Most
viral protein coding sequences in the NCBI database (84%)
were represented in the Pfam database; the remainder were
mapped by using pairwise BLAST alignments (8). The
rRNA sequences of fungi, bacteria, and parasites obtained
from the Ribosomal Database Project (RDP,
http://rdp.cme.msu.edu) or the NCBI database were added
to create a panmicrobial database (GreenePmdB). The
GreenePmdB comprises the 228,638 viral sequences of the
GreeneVrdB that represent complete and partial viral
genomes, and 41,790 bacterial 16S rRNAs, 4,109 fungal
18S rRNAs, and 2,626 18S parasitic rRNAs. These
sequences represent all recognized 1,710 vertebrate virus
species and 135 bacterial, 73 fungal, and 63 parasite genera.
GreeneChip Design and Fabrication
Viral probes were designed to represent a minimum of
3 distinct genomic target regions for every family or genus
of vertebrate virus in the ICTVdB. When possible, we
chose highly conserved regions within a coding sequence
for an enzyme such as a polymerase and 2 other regions
that corresponded to more variable structural proteins. We
thought that RNAs that encode structural proteins may be
present at higher levels than those that encode proteins
needed only in catalytic amounts and that use of probes
representing noncontiguous sites along the genome might
allow detection of naturally occurring or intentionally cre-
ated chimeric viruses.
Any diagnostic tool based on nucleic acid hybridiza-
tion is necessarily dependent on the extent to which probes
are complementary to their targets. Although sequence
databases are increasingly comprehensive, it is unlikely
that more than a fraction of the existing microbial
sequence space has been explored. Our intent in imple-
menting the GreeneChip was to have the potential to iden-
tify known and related agents for which precise sequence
information was not available. To assess the extent to
which a given probe sequence can hybridize to a non-
matching but related sequence, we analyzed synthetic mis-
match controls. Whereas up to 15 terminal mismatches had
little effect, strings of >5 mismatches distributed through-
out a sequence, particularly mismatched G/C pairs, result-
ed in reduced signal; >12 mismatches distributed
throughout a sequence resulted in no signal. On the basis
of these findings, we pursued a conservative strategy in
array design wherein a viral sequence was considered to be
covered only if the array included at least 1 complementa-
ry probe with <5 mismatches.
The process for identifying bacterial, fungal, and par-
asitic probes was similar, although restricted to 16S and
18S rRNA sequences. Viral (GreeneChipVr) and panmi-
crobial (GreeneChipPm) array platforms were based on
the GreeneVrdB and GreenePmdB, respectively.
GreeneChipVr version 1.0 contained 9,477 probes to
address all vertebrate viruses in the integrated ICTV/NCBI
database (1,710 species, including all reported isolates) in
3 gene regions with <5 nucleotide mismatches.
GreeneChipPm version 1.0 contained 29,495 probes that
included probes comprising GreeneChipVr version 1.0, as
well as 11,479 16S rRNA bacterial probes, 1,120 18S
rRNAfungal probes, and 848 18S rRNAparasite probes. A
total of 300 host immune response probes were added to
arrays as a potential index to pathogenesis.
The 60-mer oligonucleotide arrays were synthesized
on 70-mm × 20-mm glass slides by using an inkjet deposi-
tion system (Agilent Technologies, Palo Alto, CA, USA).
A slide can accept up to 244,000 different 60-mer probes
or 8 arrays, each comprising >15,000 probes. To facilitate
alignment during scanning, 1,000 additional landing-light
probes (5′-ATC ATC GTAGCTGGTCAG TGTATC CTT
TTT TTT TTA TCA TCG TAG CTG GTC AGT GTA
TCC-3′) were placed in the corners and in a grid on the
array. Fluorescently labeled synthetic oligonucleotides
complementary to the control probes were included in all
hybridizations.
Viruses and Clinical Samples
Sources of viruses and viral reference strains used in
this study are shown in Tables 1 and 2. Blood sample
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from Angola, 2005) and blood sample Angola-460 from a
patient suspected of having viral hemorrhagic fever (VHF)
were received in containers approved by the International
Air Transport Association at either the Centers for Disease
Control and Prevention in Atlanta, Georgia, USA or the
Public Health Agency of Canada in Winnipeg, Ontario,
Canada, respectively. 
Sources of clinical samples are shown in Table 3.
Nasopharyngeal aspirates (SO4606 and SO5265) were
collected by the Instituto de Salud Carlos III in Madrid,
Spain, from children with respiratory disease. We also ana-
lyzed a nasopharyngeal aspirate (sample 23), a post-
mortem specimen from a patient who died of infection
with severe acute respiratory syndrome coronavirus
(SARS-CoV, sample TM-167), urine specimens from 2
patients with urinary tract infections (samples CUMC-
NR7 and CUMC-NR9), a urine specimen from an asymp-
tomatic patient (sample CUMC-LO1), and endometrial
and lung tissues from a patient infected with
Mycobacterium tuberculosis (samples CUMC-DL1 and
CUMC-DL3). 
Sample Preparation and GreeneChip Hybridization
RNA was isolated from blood of VHF patients by
using a 6100 Nucleic Acid PrepStation (Applied
Biosystems, Foster City, CA, USA). RNA from virus iso-
lates (culture supernatant) and other clinical samples
(blood, nasopharyngeal aspirate, tissue, urine) was isolat-
ed by using the Tri-Reagent (Molecular Research Center
Inc., Cincinnati, OH, USA). DNAwas removed from RNA
preparations by treatment with DNase I (DNA-free,
Ambion Inc., Austin, TX, USA). First-strand reverse tran-
scription was initiated with a random octamer linked to a
specific primer sequence (5′-GTT TCC CAG TAG GTC
TCN NNN NNN N-3′) (5). After digestion with RNase H,
cDNA was amplified by using a 1:9 mixture of the above
primer and a primer targeting the specific primer sequence
(5′-CGC CGT TTC CCA GTA GGT CTC-3′). Initial PCR
amplification cycles were performed at a low annealing
temperature (25°C); subsequent cycles used a stringent
annealing temperature (55°C) to favor priming through the
specific sequence. Products of this first PCR were then
labeled in a subsequent PCR with the specific primer
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drimers containing >300 fluorescent reporter molecules
(Genisphere Inc., Hatfield, PA, USA), Products of the sec-
ond PCR were added to sodium dodecyl sulfate–based
hybridization buffer (Genisphere Inc.), heated for 10 min
at 80°C, and added to GreeneChip for hybridization for 16
h at 65°C. After 10-min washes at room temperature with
6 × SSC (0.9 mol/L NaCl, 0.09 mol/L sodium citrate, pH
7.0), 0.005% Triton X-100, and 0.1 × SSC, 0.005% Triton
X-100, Cy3 3DNA dendrimers were added and incubated
at 65°C for 1 h. Slides were washed as before, air
dried, and scanned (DNA Microarray scanner, Agilent
Technologies).
GreeneChip Analysis
Log-transformed analysis of microarrays using p val-
ues (GreeneLAMP) version 1.0 software was created to
assess results of GreeneChip hybridizations. A map built
from BLAST data was used to connect probe sequences to
the respective entries in the GreenePmdB. Each of those
sequences corresponds to an NCBI Taxonomy ID (TaxID).
Individual TaxIDs were mapped to nodes in a taxonomic
tree built based on ICTV virus taxonomy or the NCBI tax-
onomic classification for other organisms. The program
output is a ranked list of candidate TaxIDs.
Probe intensities were corrected for background, log2-
transformed, and converted to Z scores (and their corre-
sponding p values). Where available, control-matched
experiments from uninfected samples were used, and spots
>2 standard deviations from the mean were subtracted. In
instances where control-matched samples were not avail-
able, the background distribution of signal fluorescence in
an array was calculated by using fluorescence associated
with 1,000 random 60 mers (null probes). In both scenar-
ios, positive events were selected by applying a false-pos-
itive rate of 0.01 (the rate at which null probes are scored
as significant) and a minimum p value per probe of 0.1 in
cases with a matching control and 0.023 (2 standard devi-
ations) in cases without a matching control. Candidate
TaxIDs were ranked by combining the p values for the pos-
itive probes for that TaxID by using the QFAST method of
Bailey and Gribskov (9). This approach makes the follow-
ing assumptions: 1) spot intensities are normally distrib-
uted; 2) spots represent independent observations (to
minimize this effect clustering is used to collapse probes
that are 95% identical); and 3) there are relatively few
(<100) positive probes for any given TaxID. Probes for
each kingdom (bacteria, eukaryotes, fungi, viruses) were
analyzed independently to compensate for variations in
signal-to-noise levels.
Sequence Recovery from Hybridized Arrays
When a hybridization signal suggests a novel or
chimeric agent, or the investigator wants to obtain
sequence information, cDNA can be eluted for amplifica-
tion and sequence analysis. A total of 100 µL of water at
90°C is added to the array and pipetted up and down 10
times. The eluate is recovered, amplified with the specific
primer used during the initial amplification, and cloned
into a plasmid vector (TOPO TA, Invitrogen, Carlsbad,
CA, USA). After transformation into Escherichia coli,
colonies are screened by sequencing. Primers based on the
obtained sequence can be designed for confirmation of the
agent or for specific (real-time) PCR screening of other
specimens.
Quantitative Real-Time PCR for 
Plasmodium falciparum
A quantitative real-time PCR assay was designed to
amplify a 190-bp product from positions 178 to 367 of the
5.8S rRNA sequence eluted from the GreeneChipPm to
confirm the presence of plasmodia in the original clinical
sample. Reactions were performed in a 25-µL volume by
using a commercial SYBR-Green reaction mixture
(Applied Biosystems) and performed according to the
manufacturer’s instructions. The primer sequences were
5′-GGAACGGCTTTGTAACTTGG-3′ and 5′-TGTC-
CTCAGAGCCAATCCTT-3′. The following cycling con-
RESEARCH
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followed by 45 cycles at 95°C for 15 sec and 60°C for 1
min. To quantitate organism load in the original clinical
sample, the targeted sequence region was cloned from the
chip-hybridized, eluted nucleic acid. The cloned sequence
was used to generate a 7-point standard curve (starting
from 5 × 106 copies/assay) for quantitation; each run
included negative no-template controls. Thermal cycling
was performed in an ABI 7300 real-time PCR system
(Applied Biosystems).
Results
Evaluation of GreeneChip Performance
The performance of the GreeneChip system was ini-
tially tested in GreeneChipVr hybridizations that used
extracts of cultured cells infected with adenoviruses,
alphaviruses, arenaviruses, coronaviruses, enteroviruses,
filoviruses, flaviviruses, herpesviruses, orthomyxoviruses,
paramyxoviruses, poxviruses, reoviruses, and rhab-
doviruses (49 viruses). All viruses were accurately identi-
fied (Tables 1 and 2). To assess sensitivity, viral RNA
extracted from infected cell supernatants (adenovirus,
West Nile virus, Saint Louis encephalitis virus, respiratory
syncytial virus, enterovirus, SARS-CoV, and influenza
virus) was quantitated by real-time PCR, serially diluted,
and subjected to analysis with template concentrations
ranging from 10 to 1,000,000 copies/assay. The threshold
for detection of adenovirus (used as a DNAvirus example)
was 10,000 RNA copies; the threshold for detection of the
RNA viruses tested was 1,900 RNA copies (Table 4).
Array performance was then tested by using samples
obtained from patients with respiratory disease, hemor-
rhagic fever, tuberculosis, and urinary tract infections. In
all cases, array analysis detected an agent consistent with
the diagnosis obtained by culture or PCR. GreeneLAMP
analysis detected human enterovirus A, human respiratory
syncytial A virus, influenza A virus, Lake Victoria mar-
burgvirus (MARV), SARS-CoV, lactobacillus, mycobacte-
ria, and gammaproteobacteria (Table 3). Specific real-time
PCR analyses indicated viral loads of 6.3 × 105
copies/assay for SARS-CoV (10), 1.1 × 103 copies/assay
for respiratory syncytial virus (11), and 5.46 × 105
copies/assay for enterovirus A (12) in clinical specimens.
Details of the array analysis process are presented below
for the detection of 2 viruses and 2 bacteria in clinical
specimens.
Sample 200501379 contained RNAextracted from the
blood of a person who died of VHF. In GreeneLAMP
analysis, MARV TaxID 11269 was the top prediction by
the combined p-value method using QFAST (9). The high-
est relative number of positive probes (10/11, 90.9%) also
corresponded to MARV (Figure 1A). In contrast, only 2 of
16 probes were positive for the next best predicted TaxID
11901, bovine leukemia virus. Sequence-based analysis
identified GenBank accession no. DQ447653 (Lake
Victoria marburgvirus–Angola2005 strain Ang1379c) with
8 positive probes as the best match. The 10 positive probes
aligned with all 8 MARV gene motifs represented on the
array (Figure 1B). Only 4 (17%) of 23 probes were posi-
tive for the next best predicted GenBank entry, AF534225
(Gorilla gorilla lymphocryptovirus 1); all aligned with
only 1 motif.
Sample TM-167 contained RNA extracted from the
lung of a person who died from SARS during the 2003 out-
break in Toronto, Ontario, Canada. In GreeneLAMPanaly-
sis, SARS-CoV was the top prediction by the combined
p-value method. The highest relative number of positive
probes (9/20, 45.0%) also corresponded to SARS-CoV.
Sequence-based analysis identified GenBank accession no.
AY274119 (SARS-CoV Tor2) with 9 probes representing
9 distinct genome motifs. The next best prediction was for
AY738457 (influenza A virus); all influenza virus probes
represented only 1 genome motif.
Analyses of bacterial samples were more complex
because many rRNA probes are cross-reactive between
taxa, and the GreeneLAMP algorithm is not designed to
take into account >100 probes positive for 1 TaxID. Thus,
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with 1 genus-level TaxID. This strategy identified
mycobacteria in sample CUMC-DL3 and lactobacilli in
sample CUMC-LO1. In sample CUMC-DL3, the
sequence-based algorithm identified AY725810 (uncul-
tured Mycobacterium sp.) as significant, with 231 positive
probes across 6 nonoverlapping regions. In sample
CUMC-LO1, AJ853317 (Lactobacillus vaginalis) was the
most significant result with 87 positive probes. Consensus
PCR assays were developed for mycobacteria and lacto-




GATG-3′ (reverse); Lacto_817: 5′-CGGTGGAATGCG-
TAGATATATGGA-3′ (forward); and Lacto_1026:
5′-TCCTTTGAGTTTCAACCTTGCGGT-3′ (reverse).
Products obtained after PCR amplification were sequenced
and matched the predicted GenBank entries.
Analysis of Unknown Sample from Patient 
with VHF-like Syndrome
Within 6–8 days of infection, MARV causes an acute
febrile illness that frequently progresses to liver failure,
delirium, shock, and hemorrhage (13,14). From October
2004 through July 2005, a MARV outbreak in Angola
resulted in 252 cases of hemorrhagic fever; 227 (90%)
cases were fatal (15). Although most of the putative cases
infected with MARV were confirmed by PCR, some were
not. During this outbreak, a healthcare worker from a non-
governmental organization had acute fever and liver fail-
ure that culminated in death within 1 week. PCR assays of
RNA extracted from blood showed no evidence of MARV
infection. The same RNA was tested in a multiplex PCR
for VHF that used primers for detection of Zaire Ebola,
Sudan Ebola, MARV, Lassa fever, Rift Valley fever,
Crimean-Congo hemorrhagic fever, Hantaan, Seoul, yel-
low fever, and Kyasanur Forest disease viruses (3) for dif-
ferential diagnosis of VHF. Because this test did not
identify an etiologic agent, the RNA was processed for
panviral analysis with GreeneChipVr. Because no signifi-
cant hybridization was detected, the RNA was assayed
with GreeneChipPm. Bioinformatic analysis identified a
Plasmodium  sp. with 21 (62%) of 34 probes positive
(Table 5). Chart review showed that the patient had recent-
ly arrived in Angola from a country where malaria was not
endemic and that he had not taken malaria prophylaxis.
Hybridized cDNA was eluted from the array, cloned,
and sequenced. Identified clones contained sequences cor-
responding to 18S rRNA and 5.8S rRNA of P. falciparum
(Figure 2, Table 6). Plasmodia contain several alternative
18S-5.8S–28S rRNA genes. The expression of each rRNA
set is developmentally regulated, which results in expres-
sion of a different set of rRNAs at different stages of the
life cycle of the organism (17); e.g., S-type rRNA is
expressed primarily in the mosquito vector, but A-type
rRNA is expressed primarily in the human host (17). Only
A-type sequences were recovered from the array. Analysis
of the original RNA extract in a SYBR Green real-time
PCR assay designed to amplify a 190-bp product of the P.
falciparum 5.8S rRNA gene confirmed the presence of P.
falciparum (2 × 106 ± 8 × 104 copies/µL blood), and indi-
cated a parasite load >5%. The similarity of the signs and
symptoms of severe malarial disease with viral hemor-
rhagic disease, the detection of a parasite load >5% (18),
and the origin of this patient from a country nonendemic
for malaria are consistent with a diagnosis of infection
with P. falciparum as the most likely cause of death.
Discussion
Differential diagnosis of hemorrhagic fevers poses
challenges for clinical medicine and public health.
Syndromes associated with agents are not distinctive, par-
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Figure 1. A) Signal intensity for viral probes in blood sample
200501379. Probe intensities were background corrected, log2-
transformed, and converted to Z scores (and corresponding p val-
ues). Background distribution of signal fluorescence in the array
was calculated by using fluorescence associated with 1,000 ran-
dom null probes. Positive events were selected by applying a min-
imum p value per probe of 0.023 (2 standard deviations). Analysis
of positive events with GreeneLAMP resulted in prediction of TaxID
11269 as the top prediction by the combined p value. Solid
squares indicate Lake Victoria marburgvirus probes; open trian-
gles indicate other probes. Ten of (90.9%) of 11 Lake Victoria mar-
burgvirus probes were positive. B) Genomic location of positive
Lake Victoria marburgvirus probes. Sequence-based analysis
identified GenBank accession no. DQ447653 (Lake Victoria mar-
burgvirus–Angola2005 strain Ang1379c) with 10 positive probes
(all 8 motifs) as the best match.ticularly early in the course of disease. In some instances,
including the case presented here, more than 1 agent may
be endemic in the region of the outbreak. Outbreaks
caused by different agents may also overlap in time and
geography. Examples of such coincident outbreaks include
monkeypox and varicella-zoster viruses in the Democratic
Republic of Congo in 1996 and 2001 (19,20) and measles
and Ebola viruses in Sudan in 2004 (21). Furthermore,
implicit in globalization is the risk of known or new agents
that appear in novel contexts. In 1996, a presumptive diag-
nosis of Ebola VHF in 2 children who had recently
returned to New York City from West Africa resulted in
closing a hospital emergency room (22). One of the chil-
dren died of cardiac failure caused by P. falciparum para-
sitemia and hemolysis (23). Therapeutic options for
treatment of VHF are limited; however, rapid isolation of
infected persons is critical to curb contagion. In contrast,
whereas human-to-human transmission is not a primary
concern with malaria, early specific therapy can have a
profound effect on illness and death (24).
To address the challenges of emerging infectious dis-
eases and biodefense, public health practitioners and diag-
nosticians need a comprehensive set of tools for pathogen
surveillance and isolation. PCR methods have advantages
with respect to sensitivity, throughput, and simplicity, but
are limited in potential for multiplexing. Although
microarrays have potential to allow highly multiplexed,
unbiased surveillance, their use has been limited because
of low sensitivity and unwieldy analytical programs. The
GreeneChip system introduces sample preparation and
Array for Diagnosis of Infectious Diseases
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Figure 2. Analysis of 18S rRNA sequence (nt
291,256–292,364) recovered from the array
after hybridization of sample Angola-460. The
phylogenetic tree was reconstructed with the
neighbor-joining method applying a Kimura 2-
parameter model with MEGA version 3.1 (16).
Number of nucleotide substitutions per site are
indicated by the scale bar; bootstrap values
(percentage of 1,000 pseudoreplicates) are
given at relevant branches. Circles indicate
Plasmodium falciparum sequences; inverted tri-
angles indicate other known plasmodial
pathogens of humans. labeling methods that enhance sensitivity, as well as user-
friendly analytical software that we anticipate will facili-
tate clinical application. The advent of validated highly
multiplexed microbiologic assays will afford unprecedent-
ed opportunities for unbiased pathogen surveillance and
discovery and reduction of illness and death caused by
infectious disease.
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